Speciality Medicines Limited is engaged in the marketing and distribution of speciality pharmaceutical formulations, focusing on high-cost oral and injectable medicines used to treat complex and chronic health conditions across both domestic and international markets.
The company offers a diversified portfolio of speciality pharmaceutical formulations available in multiple dosage forms, including:
- Tablets & capsules
- Creams, gels & ointments
- Syrups & suspensions
- Eye drops & ophthalmic solutions
- Injections & infusions
- Inhalers & nasal sprays
- Oral solutions & sachets
Speciality Medicines Limited operates through a dual business model:
- Contract Manufacturing (International Focus): Manufactures finished formulations for global markets, catering to international pharmaceutical demand.
- Marketing & Distribution: Sources and distributes specialty pharmaceutical products across domestic and international markets.
Operations across 20+ Indian states and 35+ countries, with product registrations in markets like Jordan, Ethiopia, Uganda, Peru, and Namibia.
As of March 31, 2025, the company has 1 product registered overseas and 60 under registration across 5 countries, contributing to ongoing international revenue.
As of August 31, 2025, the company operates with a lean team of 18 permanent employees.
Speciality Medicines IPO – Details
| IPO Opening Date | 20 March 2026 |
| IPO Closing Date | 24 March 2026 |
| Issue Type | Book Built Issue IPO |
| Issue Size | Total Issue: 23,50,000 Shares Worth ₹29.14 Crore Fresh Issue: 23,50,000 Shares Worth ₹29.14 Crore |
| Face Value | ₹10 per equity share |
| IPO Price | ₹117 – ₹124 per share |
| Market Lot | 1000 Shares |
| Min Order | 1000 Shares [ 1 Lot ] |
| Listing At | BSE SME |
| Registrar | Skyline Financial Services Pvt. Ltd. |
| QIB Shares Offered | 0.96% |
| NII Shares Offered | 49.50 |
| Retail Shares Offered | 49.54% |
Speciality Medicines IPO – Date Schedule
| IPO Open Date | 20 March 2026 |
| IPO Close Date | 24 March 2026 |
| Basis of Allotment | 25 March 2026 |
| Initiation of Refund | 27 March 2026 |
| Credit of Shares to Demat | 27 March 2026 |
| IPO Listing Date | 30 March 2026 |
| Cut-off time for UPI mandate confirmation | 5 PM on March 24, 2026 |
Speciality Medicines IPO – Lots Size & Price
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 2 | 2,000 | ₹2,48,000 |
| Retail (Max) | 2 | 2,000 | ₹2,48,000 |
| S-HNI (Min) | 3 | 3,000 | ₹3,72,000 |
| S-HNI (Max) | 8 | 8,000 | ₹9,92,000 |
| B-HNI (Min) | 9 | 9,000 | ₹11,16,000 |
Competitive Strength
- Diversified Global Presence.
- Diverse product portfolio.
- Long Standing Client Relationship.
- Experienced Promoters and Management Team.
- Quality Assurance.
Company Promoters
- Parth B Goyani
- Goyani Sumit Babubhai
Company Financials
| Period | Total Revenue | Total Expense | Profit After Tax | Total Borrowings |
|---|---|---|---|---|
| 31 March 2023 | ₹23.20 Cr | ₹20.24 Cr | ₹1.70 Cr | ₹3.64 Cr |
| 31 March 2024 | ₹27.66 Cr | ₹23.10 Cr | ₹2.93 Cr | ₹2.86 Cr |
| 31 March 2025 | ₹58.54 Cr | ₹49.85 Cr | ₹8.61 Cr | ₹5.05 Cr |
| 31 October 2025 | ₹36.93 Cr | ₹30.80 Cr | ₹6.06 Cr | ₹4.81 Cr |
Key Performance Indicator
| KPI | Values (Oct 31, 2025) |
|---|---|
| ROE | 18.11% |
| ROCE | 16.68% |
| Debt/Equity | 0.13 |
| RoNW | 16.61% |
| PAT Margin | 16.49% |
| EBITDA Margin | 17.73% |
| Price to Book Value | 2.19 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 13.38 | 11.82 |
| P/E (x) | 9.27 | 10.49 |
Object Of The Issue
| Objects of the Issue | Expected Amount (in Crore) |
|---|---|
| Setting up of Research and Development (R&D) Center. | ₹12.68 |
| Product registration and Development in the international markets. | ₹2.99 |
| Funding for Marketing and Brand Promotion Activities. | ₹1.66 |
| To Meet Working Capital Requirements. | ₹8.00 |
| General corporate purposes. | – |
✅Strengths
- Niche speciality pharma segment (high margin).
- Presence in 35+ countries.
- Dual model (contract manufacturing + distribution).
- 60+ products pipeline for future growth.
- Wide product portfolio.
- Asset-light, scalable operations.
⚠️Risks
- High dependence on international markets.
- Regulatory approval delays risk.
- Dependency on third-party suppliers.
- Limited operating history (since 2021).
- Small team (execution risk).
- Highly competitive industry.
Speciality Medicines IPO Promoter Holding
| Pre-Issue Share Holding | 59.28% |
| Post Issue Share Holding | 43.44% |
Speciality Medicines IPO Prospectus
Company Contact Information
| Speciality Medicines Ltd. 913, One World West, S. No. 396, FP 119, Village- Vejalpur, Ahmadabad City, Gujarat, India, 380051 Phone: +91 22 4604 5344 Email: investors.grievances@specialitymedicine.com Website: https://www.specialitymedicine.com/ |
Speciality Medicines IPO Registrar
| Skyline Financial Services Pvt. Ltd. Phone: 02228511022 Email: ipo@skylinerta.com Website: https://www.skylinerta.com/ipo.php |
Speciality Medicines IPO Lead Manager(s)
| 1. Unistone Capital Private Limited |
Speciality Medicines IPO FAQ
| What is the Speciality Medicines IPO? Speciality Medicines IPO is an SME IPO. The issue is priced at ₹117 – ₹124 per equity share. The IPO is to be listed on BSE SME. |
| When will Speciality Medicines IPO open? The IPO is to open on 20 March 2026 for QIB, NII, and Retail Investors. |
| What is Speciality Medicines IPO Investors’ Portion? The investors’ portion for QIB – 0.96%, NII – 49.50%, and Retail – 49.54%. |
| What is the Speciality Medicines IPO Size? Speciality Medicines IPO size is ₹29.14 Crore. |
| What are the Speciality Medicines IPO Minimum and Maximum Lot Sizes for Retail Investors? The minimum bid is 2000 Shares for ₹2,48,000, while the maximum bid is 2000 Shares for ₹2,48,000. |
| What is the Speciality Medicines IPO Allotment Date? Speciality Medicines IPO allotment date is 25 March 2026. |
| What is the Speciality Medicines IPO Listing Date? Speciality Medicines IPO listing date is 30 March 2026. The IPO is to be listed on the BSE SME. |
